Literature DB >> 16222731

Treatment of Zollinger-Ellison syndrome.

Paola Tomassetti1, Davide Campana, Lydia Piscitelli, Elena Mazzotta, Emilio Brocchi, Raffaele Pezzilli, Roberto Corinaldesi.   

Abstract

In this article, we have reviewed the main therapeutic measures for the treatment of Zollinger-Ellison syndrome (ZES). Review of the literature was based on computer searches (Pub-Med, Index Medicus) and personal experiences. We have evaluated all the measures now available for treating patients with sporadic gastrinomas or gastrinomas associated with Multiple Endocrine Neoplasia Type 1, (MEN 1) including medical therapy such as antisecretory drugs and somatostatin analogs (SST), chemotherapy and chemoembolization, and surgical procedures. In ZES patients, the best therapeutic procedure is surgery which, if radical, can be curative. Medical treatment can be the best palliative therapy and should be used, when possible, in association with surgery, in a multimodal therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16222731      PMCID: PMC4320348          DOI: 10.3748/wjg.v11.i35.5423

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  104 in total

1.  THE ZOLLINGER-ELLISON SYNDROME: RE-APPRAISAL AND EVALUATION OF 260 REGISTERED CASES.

Authors:  E H ELLISON; S D WILSON
Journal:  Ann Surg       Date:  1964-09       Impact factor: 12.969

Review 2.  Chemotherapy of endocrine malignancies: a review.

Authors:  L K Kvols; M Buck
Journal:  Semin Oncol       Date:  1987-09       Impact factor: 4.929

3.  Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin.

Authors:  I M Murray-Lyon; A L Eddleston; R Williams; M Brown; B M Hogbin; A Bennett; J C Edwards; K W Taylor
Journal:  Lancet       Date:  1968-10-26       Impact factor: 79.321

4.  Surgical resection of intracardiac gastrinoma.

Authors:  S Noda; J A Norton; R T Jensen; W A Gay
Journal:  Ann Thorac Surg       Date:  1999-02       Impact factor: 4.330

5.  Slow-release lanreotide treatment in endocrine gastrointestinal tumors.

Authors:  P Tomassetti; M Migliori; L Gullo
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

Review 6.  Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop.

Authors:  B Wiedenmann; R T Jensen; M Mignon; C I Modlin; B Skogseid; G Doherty; K Oberg
Journal:  World J Surg       Date:  1998-03       Impact factor: 3.352

Review 7.  Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.

Authors:  A B Thomson
Journal:  Curr Gastroenterol Rep       Date:  2000-12

Review 8.  Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors.

Authors:  G Rindi; V Villanacci; A Ubiali
Journal:  Digestion       Date:  2000       Impact factor: 3.216

9.  Pancreatic venous sampling and arteriography in localizing insulinomas and gastrinomas: procedure and results in 55 cases.

Authors:  A Roche; A Raisonnier; M C Gillon-Savouret
Journal:  Radiology       Date:  1982-12       Impact factor: 11.105

Review 10.  Zollinger-Ellison syndrome. Current concepts in diagnosis and management.

Authors:  M M Wolfe; R T Jensen
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

View more
  5 in total

1.  Prospective evaluation of quality of life in patients with Zollinger-Ellison syndrome.

Authors:  George B Smallfield; Jeroan Allison; C Mel Wilcox
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

2.  Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency.

Authors:  Kei Nakajima; Haruki Oshida; Toshitaka Muneyuki; Masafumi Kakei
Journal:  Core Evid       Date:  2012-07-19

3.  Proton Pump Inhibitors Modulate Transport Of Doxorubicin And Its Liposomal Form Into 2D And 3D Breast Cancer Cell Cultures.

Authors:  Miglė Paškevičiūtė; Vilma Petrikaitė
Journal:  Cancer Manag Res       Date:  2019-11-21       Impact factor: 3.989

Review 4.  Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.

Authors:  Yuheng Hu; Zeng Ye; Fei Wang; Yi Qin; Xiaowu Xu; Xianjun Yu; Shunrong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-19       Impact factor: 5.555

Review 5.  Causes of Exocrine Pancreatic Insufficiency Other Than Chronic Pancreatitis.

Authors:  Lumír Kunovský; Petr Dítě; Petr Jabandžiev; Michal Eid; Karolina Poredská; Jitka Vaculová; Dana Sochorová; Pavel Janeček; Pavla Tesaříková; Martin Blaho; Jan Trna; Jan Hlavsa; Zdeněk Kala
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.